This essay is about that ubiquitous phrase in pharma, “for the patients,” and the structure that sits behind it. The aim is not criticism, nor to condemn anyone. I only want to pause and look again at the path by which my own work gets converted into “for the patient” ── and to record that this was what led me to build this site.
01A Phrase Everywhere
“For the patients” is one of the most frequently used phrases in the pharmaceutical industry. You hear it on the first day of onboarding, at product briefings, in the rooms where decisions are made. It becomes a refuge in moments of doubt: when unsure, ask whether it serves the patient.
There is nothing wrong with that in itself. In many situations it points people in the right direction. The problem is that the phrase is recited with so little resistance, so little verification. No one objects. No one can. No one can claim to be against patients. And so the phrase also becomes a device that stops thought.
02Hard to See Because There Is No Malice
My unease is not that someone is lying. The opposite: almost everyone means it sincerely. That is precisely what makes it difficult. A pretense built on bad faith can be seen through. But conditioning that comes from genuine belief is invisible even to the person holding it.
“Conditioning,” “indoctrination” ── perhaps those words are too strong. Still, I feel something close to them. You join, you train, the people around you use the same words, and your performance is described in those words too. Before long, the conversion happens automatically: my work is “for the patient.” The very circuit that would question it quietly falls out of use.
03A Corporation’s Mission Is Profit
Let me look at the structure calmly. Most Japanese pharmaceutical companies are joint-stock corporations. A corporation’s fiduciary duty runs, in the first instance, to its shareholders. Its mission, put plainly, is to generate profit and raise enterprise value. This is not a criticism; it is the definition of the institution.
Within that, the labor of each person on the ground is given, through some path, the meaning of being “for the patient.” But follow the flow of money to the end, and the value that labor produces ultimately goes to management and shareholders ── to capital. There is no way around this. It is the structure of the system, not a question of individual virtue or vice.
| Stated (slogan) | Actual structure | |
|---|---|---|
| Primary aim | Patient benefit | Profit maximization (duty to shareholders) |
| Ultimate beneficiary | Patients | Shareholders / management (capital) |
| Function of the phrase | Motivation | Self-justification and mobilization |
| How it is checked | Recited in chorus | Almost never questioned |
| What backs the “for” | Good intentions | Learning the history of drug harm and ethics |
Do not misread me. Profit itself is not evil. Without it, neither research nor supply could continue. Patient interest and corporate interest often overlap. The question is what is prioritized when the two diverge ── and whether one can notice that they have diverged at all.
04Where the Automatic Conversion Happens
The conversion of “my work is for the patient” travels a subtle path. Sales targets are framed as “delivering the drug to more patients.” Indication expansion becomes “saving more patients.” Even strengthening the wording of a promotional piece can be called “communicating accurately.” No single rephrasing is a lie. But stacked together, the pursuit of profit and the interest of patients become indistinguishable.
A pretense built on bad faith can be seen through. Conditioning that comes from genuine belief is invisible even to the person holding it.
05Holding the Structure in View
So what can be done? The structure itself cannot be changed by an individual. This is not a call to abolish the corporation. What I mean is something far humbler: to keep recognizing this structure as a structure. To not forget which path my “for the patient” travels, and whose benefit it finally becomes.
Metacognition looks powerless, but it is not. Those who can notice the divergence can hold their ground when it appears. When a promotional piece is about to cross a line, when there is a temptation to dilute a negative result, one can ask again: is this truly for the patient, or for the numbers? Whether one can keep holding that question is, I think, the only freedom left to the individual.
06If You Truly Mean It
If you truly mean “for the patients,” there are things to learn. Not to recite a slogan, but to know how patients were harmed in the past and how those lessons became institutions. Yet on the ground, I have rarely met anyone who has studied that far.
The history of drug harm
Thalidomide, SMON (clioquinol), HIV-tainted blood products, sorivudine. Know, concretely, why they were not prevented and who prioritized what.
Patient protection
Informed consent, patient self-determination, protection of research subjects ── the lineage of treating patients as agents, not “subjects.”
Medical ethics
The Nuremberg Code, the Declaration of Helsinki, the three Belmont principles (respect for persons, beneficence, justice).
Research ethics
Disclosure of conflicts of interest, data integrity, reproducibility. Whose funding, whose analysis, who wrote the conclusion.
Publication ethics
ICMJE standards, ghostwriting, spin, non-publication of negative results. How papers are made ── and how they bend.
These are not the stuff of difficult monographs. Most are public declarations and guidelines, freely readable by anyone. The right to say “for the patient,” I believe, belongs only to those who have once worked through these with their own mind. At the very least, one should read before reciting.
07Why I Built This Site
This unease is what led me to build this site. I wanted to set down the regulation and ethics of pharma and medicine not as slogans but grounded in primary sources, in concrete detail. Why drug harm occurred, what advertising regulation was born to protect, where the line in material review actually lies. I wanted to place these as objects of study, not of chant.
I cannot deny the structure of capital. I work within it. That is exactly why I want, at least, to not lose sight of the structure ── to hold “for the patients” not as an incantation that stops thought, but as a question that catches every time. That is the one thing I do not want to let go of while continuing this work.
“For the patients” is a beautiful phrase. That is exactly why it is dangerous. Beautiful phrases are easily put to mobilization without ever being checked. Even without malice ── no, precisely because there is no malice ── it imprints itself quietly.
I do not want to discard this phrase. I want, rather, to give it real meaning. And for that, the only way is to stop reciting, to learn, to keep the structure in view, and to hold one’s ground when things diverge. Turning a slogan into an implementation is humble work, and it never ends.
Each day a good day ── on any day, never letting go of thinking. In the very moment I am about to say “for the patients,” I doubt it once more. That small resistance is what I would like to keep practicing.
- “For the patients” is, in most cases, recited without malice. But the absence of malice is exactly what makes the conditioning hard to see.
- A corporation’s fiduciary duty runs to shareholders. The starting point is to keep recognizing, as a structure, the path by which one’s labor is automatically converted into “for the patient.”
- If you truly mean it, learn the history of drug harm, patient protection, and medical, research, and publication ethics. Not a slogan but study and institutions are what back it.
- World Medical Association. Declaration of Helsinki ── Ethical Principles for Medical Research Involving Human Subjects.
- The National Commission. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. 1979.
- Nuremberg Military Tribunal. The Nuremberg Code. 1947.
- ICMJE. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.
- Ministry of Health, Labour and Welfare (Japan). Educational materials on learning from drug-induced harm ── thalidomide, SMON, HIV-tainted blood products, sorivudine.